Researchers reporting in PLOS Pathogens say drug repurposing screens have uncovered a role for the human proteins PKCη and NF1 in SARS-CoV-2 infection. The study adds to the effort to identify host cell mechanisms the coronavirus depends on, rather than focusing only on viral mutations that can shift from one variant to another.
The work is notable because SARS-CoV-2 continues to evolve in ways that can weaken existing immunity, yet it still relies on key processes inside human cells to enter and spread. By using repurposing screens, scientists can look for already known compounds or pathways that interfere with those shared cellular requirements and may point toward broader antiviral strategies.
According to the author summary, the findings suggest PKCη and NF1 are part of the cellular machinery that supports successful infection. That makes them potential targets for further investigation as researchers search for treatments that remain useful even as the virus changes.
The study does not by itself establish a finished therapy, but it strengthens the case for host-directed approaches to COVID-19. If conserved human cell factors can be safely targeted, future drugs may have a better chance of staying effective against multiple SARS-CoV-2 variants.
